Application and clinical impact of the RESIST-4 O.K.N.V. rapid diagnostic test for carbapenemase detection in blood cultures and clinical samples by Roth, Sophie et al.
BRIEF REPORT
Application and clinical impact of the RESIST-4 O.K.N.V.
rapid diagnostic test for carbapenemase detection in blood cultures
and clinical samples
Sophie Roth1 & Fabian K. Berger1 & Andreas Link2 & Anna Nimmesgern1 & Philipp M. Lepper3 & Niels Murawski4 &
Jörg T. Bittenbring4 & Sören L. Becker1
Received: 13 July 2020 /Accepted: 24 August 2020
# The Author(s) 2020
Abstract
Invasive infections caused by carbapenemase-producing bacteria are associated with excess mortality. We applied a rapid
diagnostic test (RDT) on clinical samples with an elevated likelihood of carbapenemase-producing bacteria and documented
its impact on antibiotic treatment decisions. Among 38 patients, twelve tested positive for infections caused by carbapenemase-
producing bacteria (31.6%), mainly in blood cultures. KPC (n = 10) was more frequent than OXA-48 (n = 2). RDT-based
carbapenemase detection led to a treatment modification to ceftazidime/avibactam-containing regimens in all patients before
detailed antibiotic testing results became available. Eleven patients (92%) survived the acute infection, whereas one patient with a
ceftazidime/avibactam- and colistin-resistant OXA-48-positive isolate died.
Keywords Antibiotics . Clinical microbiology . Diagnostic stewardship . Enterobacterales . Escherichia coli . Klebsiella
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Introduction
Increasing antimicrobial resistance is among the biggest threats
to global health. Resistance in gram-negative bacteria is partic-
ularly worrying, e.g. Enterobacterales and non-fermentative
bacteria that produce carbapenemases, leading to non-
susceptibility to all carbapenem antibiotics. Carbapenemase-
carrying plasmids are easily transferred to other bacteria
through horizontal gene transfer. A significant increase in
carbapenemase-producing bacteria such as Klebsiella
pneumoniae in high-income countries is associated with an
excess mortality of up to 50% [1], with inadequate empirical
treatment and delayed diagnosis of carbapenem resistance be-
ing major contributing factors [2, 3]. It is pivotal to reduce the
time to appropriate antimicrobial treatment by early detection of
multiresistant pathogens and to elucidate the underlying resis-
tance mechanism to switch treatment, e.g. to new beta-lactam/
beta-lactamase inhibitor combination antibiotics such as
ceftazidime/avibactam or the siderophore cephalosporin
cefiderocol with a broad activity against frequently isolated
carbapenemases in Europe, i.e. KPC and OXA-48 [4].
Recently, immunochromatographic rapid diagnostic tests
(RDTs) to detect different carbapenemases in culture-grown
bacteria within 10–20 min have been introduced. In the pres-
ent study, we investigated the diagnostic accuracy and subse-
quent impact on clinical decision-making of the RESIST-4
O.K.N.V. test, an RDT for carbapenemase detection in clini-
cal samples.
Methods
This study was conducted at the Saarland University Medical
Center, a tertiary care centre in Homburg, Germany. We eval-
uated themicrobiological characteristics and clinical impact of
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the RESIST-4 O.K.N.V. RDT (Coris BioConcept; Gembloux,
Belgium) for rapid carbapenemase detection and compared it
to a commercially available multiplex PCR test (RDB2290
Carbapenemase , Autoimmun Diagnostika GmBH;
Straßberg, Germany). The RDT was previously validated for
application on culture-grown bacterial colonies and uses spe-
cific monoclonal antibodies directed against OXA-48, NDM,
KPC and VIM-1 carbapenemases. The test was performed
according to the manufacturer’s instructions [5].
In the first phase of this study (30 April 2018–30 April
2019), the RDT was applied on clinical samples with growth
of gram-negative bacteria and decreased susceptibility to
ertapenem, imipenem and/or meropenem, as detected by au-
tomated resistance testing using the VITEK2 system
(BioMérieux; Marcy-L’Étoile, France).
In the second study phase (1 July 2019–30 April 2020), the
RDT was directly applied on the pellet from blood cultures
within 2 h after they became positive for Escherichia coli,
K. pneumoniae or Pseudomonas aeruginosa, as identified
by the MALDI Sepsityper (Bruker Daltonics; Bremen,
Germany). To this end, 1 ml of blood culture fluid was trans-
ferred to a microcentrifuge tube, 200 μl lysis buffer (MBT
Sepsityper®, Bruker Daltonics; Bremen, Germany) was
added, and the sample was thoroughly mixed. After centrifu-
gation for 2 min, the supernatant was discarded, and 1 ml of
wash buffer was added. The solution was mixed again and
centrifuged for 1 min. Then, the pellet was mixed with 12
drops of the RDT’s LY-A buffer, and 3 drops were added to
the sample wells of both RDT cassettes, as recommended in
the manufacturer’s instructions.
Samples were included in this study when the patients had
previously documented intestinal carriage of carbapenemase-
producing bacteria or when there was an elevated likelihood
for these pathogens (e.g. septic patient non-responsive to car-
bapenem treatment). Of note, the RDT results became avail-
able before comprehensive resistance testing results were
reported.
During both phases of the study, RDT results were imme-
diately communicated to the treating clinician and were jointly
discussed, and alterations of the antibiotic treatment were
documented.
Additional clinical data were analysed using patient chart
review and documented notes from infectious disease consul-
tations. No ethics approval was required for this study.
Results
During the first study phase (12 months), the RDT was per-
formed on a total of 29 clinical samples from 27 patients that
were carbapenem-resistant on antimicrobial susceptibility
testing. The test was most frequently used on isolates from
urine samples (n = 11) and blood cultures (n = 8), followed by
wound swabs (n = 5), catheter tips (n = 1), bronchoalveolar
lavage (n = 1), cerebrospinal fluid (n = 1), abdominal drainage
fluid (n = 1) and bile (n = 1). Bacterial species subjected to the
RDT included K. pneumoniae (n = 19), Klebsiella aerogenes
(n = 4), Enterobacter cloacae complex (n = 3), Escherichia
coli (n = 1), Serratia ureilytica (n = 1) and Serratia
marcescens (n = 1).
The RDT yielded a positive result in 6/27 tested patients
(22%) and identified four KPC- and two OXA-48-producing
K. pneumoniae strains, whereas no carbapenemases were de-
tected in other bacterial species. All RDT results were con-
firmed by multiplex PCR, leading to a perfect diagnostic agree-
ment between both tests. Details on the patient characteristics,
clinical cases and the impact of RDT results on clinical man-
agement are provided in Table 1. In brief, carbapenemase de-
tection led to an antibiotic treatment modification in all six
patients, with a switch from meropenem-based regimens to
ceftazidime/avibactam-containing regimens being most fre-
quently performed. Microbiological cure and survival of the
acute infection were achieved in five of these patients. One
patient died, whose K. pneumoniae isolate was resistant to car-
bapenems, ceftazidime/avibactam, tigecycline, colistin and
aminoglycosides.
In the second study phase (10months), the RDTwas applied
on eleven positive blood culture samples stemming from eleven
patients with an increased likelihood of carbapenemase-
producing bacteria. The RDTwas positive in 6/11 (55%) cases,
all of which were identified as KPC-producing K. pneumoniae
strains. Of note, RDT test band intensities were strong, and we
did not observe faint or borderline test bands (Fig. 1). There was
a 100% diagnostic agreement between the RDT carried out on
blood culture pellets and multiplex PCR, which was performed
the next day on culture-grown colonies. While three KPC-
positive patients had previously documented intestinal carriage,
the RDT was the first test being positive for carbapenemases in
the other three patients. Treatment was modified in all patients
from carbapenem-based to ceftazidime/avibactam-containing
regimens, and all patients survived the bacteremia episode
(Table 2).
Discussion
The main findings of the present study are as follows: (i) in a
clinical setting with a relatively low incidence of
carbapenemases, the RESIST-4 O.K.N.V. test has excellent
diagnostic accuracy, with reliable results obtained from
culture-grown colonies and blood culture pellets, and (ii) im-
mediate result communication to the treating clinician most
frequently led to an early treatment modification, which likely
resulted in an improved outcome. To our knowledge, our
study is the first to report data on the test’s performance and
clinical impact if applied to blood cultures from routine
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cl inical prac t ice wi th an elevated l ikel ihood of
carbapenemases (i.e. patients with a clinical deterioration dur-
ing carbapenem treatment or known faecal carriage of
carbapenemases). Our strategy frequently led to treatment
modifications before final antimicrobial susceptibility tests
became available and was based on the epidemiological like-
lihood of, for example, KPC-positive isolates being suscepti-
ble to ceftazidime/avibactam. Hence, this RDT may provide
accurate, clinically relevant results faster and at a lower cost
than PCR tests and might thus also be promising in resource-
constrained settings with limited diagnostic infrastructure [6].
Having originally been designed to detect only one specific
type of carbapenemases, the RDT used in this study was
adapted several times to accommodate the concurrent detec-
tion of KPC and OXA-48 carbapenemases [7], with later ad-
dition of NDM [8] and VIM. In the meantime, an updated
version was developed and made commercially available,
which also includes OXA-163 [9]. Several laboratory assess-
ments have shown excellent sensitivity and specificity, as elu-
cidated by, for example, a detailed validation on clinical sam-
ples in the Belgian National Reference Centre for identifica-
tion of the mechanisms related to carbapenem resistance [5].
In a recent study, the sensitivity and specificity of the
RESIST-4 O.K.N.V. assay on culture-grown colonies were
reported at 97.8% and 100%, respectively [10]. One study,



































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 Test band intensity of the RESIST-4 O.K.N.V rapid diagnostic test
for carbapenemase detection after direct application on the pellet of a
positive blood culture. The shown test was performed on a blood culture
with a KPC-positive Klebsiella pneumoniae strain. C control line, O
OXA-48 carbapenemase, K KPC carbapenemase, V VIM
carbapenemase, N NDM carbapenemase
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multidrug-resistant gram-negative bacteria, used the RDT to
analyse 100 clinical carbapenemase isolates and showed a
100% agreement between the RDT results and molecular ref-
erence testing [11]. Of note, more recent investigations ob-
served a slightly reduced test sensitivity for detection of
NDM carbapenemases [12], which were absent in our study,
and decreased accuracy if the RDT was performed on bacte-
rial colonies from Mueller-Hinton agar as compared with
sheep blood agar [13].
A rapid diagnosis of carbapenemase-producing bacteria is
essential to guide clinical decision-making. The RDT used in
this study was designed to be performed on culture-grown
colonies on agar plates. However, previous studies employed
different versions of this RDT as a screeningmethod for faecal
carriage of multiresistant bacteria directly on rectal swabs [4],
with comparable diagnostic accuracy if compared with culture
[14]. With regard to positive blood culture bottles, a proof-of-
principle study conducted on the previous version of this RDT
(RESIST-3) showed a sensitivity and specificity of 100%,
respectively, for carbapenemase detection if blood cultures
were spiked in the laboratory with carbapenemase-producing
bacteria and the test applied on a centrifuged lysate of positive
blood cultures [15]. Of note, an additional evaluation from
Italy on spiked blood cultures elucidated that a newer version
of the RDT (RESIST-5) failed to detect KPC variants with a
D179Y point mutation and observed a lower sensitivity for
detection of VIM and NDM on blood culture pellets [9],
which is in line with findings from a previous study [16].
The D179Y point mutation may confer resistance to
ceftazidime-avibactam [17].
Our study has some limitations. First, the sample size in our
exploratory single-centre study was small, and there is a need
for larger, prospective studies to confirm the clinical utility of
our approach. Second, we did not consistently use a specific
grading system to document the RDT’s test band intensity,
which is reported to vary across clinical samples [18] and
‘trace’ results might pose a diagnostic challenge. Third, we only
evaluated one RDT, the RESIST-4 O.K.N.V., on samples pos-
itive for OXA-48 and KPC, whereas other RDTs have shown
comparable diagnostic accuracy [19]. Fourth, the emerging re-
sistance to ceftazidime/avibactam, which was frequently used
in our study for the treatment of carbapenemase-producing bac-
teria, might limit the utility of our approach [20]. Indeed, we
observed one K. pneumoniae strain resistant to ceftazidime/
avibactam, but did not further specify the underlying resistance
mechanism. This should be addressed in future investigations.
However, this development might be counterbalanced by the
introduction of new antibiotics such as cefiderocol or
meropenem/vaborbactam, which might be suitable alternatives
for infections caused by bacteria with OXA-48 or KPC
carbapenemases.
In conclusion, the RDT used in this study showed excellent
diagnostic accuracy to detect KPC andOXA-48 carbapenemases
in clinical samples. The RDT provided reliable results in less
than 30min, both on culture-grown colonies as well as on pellets
from positive blood cultures. Most importantly, carbapenemase
detection always led to a treatment modification—frequently be-
fore additional antibiotic testing results became available—and
might have improved patient outcome. Further studies are war-
ranted to investigate the effects of such rapid diagnostics and
close collaboration between clinical and diagnostic infectious
disease disciplines to improve patient management.
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